KRAS and lung adenocarcinoma: Lung adenocarcinomas with concurrent KRAS and TP53 mutations are more responsive to PD1/PD-L1 inhibitors, whereas tumors with KRAS and STKII co-mutations exhibit resistance to those inhibitors [11,12].